VisCardia Press Releases

• Published on June 10, 2025 - 14:52 GMT

  

  VisCardia Wins Inaugural MedTech Innovator Impact Award at 32nd Annual Medical Device & Digital Health Conference

  PORTLAND, OR, UNITED STATES, June 10, 2025 /⁨EINPresswire.com⁩/ -- VisCardia, Inc., an alumni company of MedTech Innovator, has been awarded the first-ever 2025 MedTech Innovator Impact Award on Friday, June 6, during the live pitch session at the 32nd …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on May 21, 2025 - 15:49 GMT

  

  VisCardia Honored with Prestigious Innovation Award at EuroPCR 2025 for Groundbreaking Heart Failure Therapy

  PARIS, FRANCE, May 21, 2025 /⁨EINPresswire.com⁩/ -- VisCardia, Inc., the developer of a disruptive therapy for heart failure, proudly announced today that it has received the prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on April 4, 2025 - 10:00 GMT

  ACC.25 Panel of Experts Awards VisCardia Top Honors for Innovation in MedTech

  VisCardia wins ACC.25 Innovation Pitch Competition Award PORTLAND, OR, UNITED STATES, April 4, 2025 /⁨EINPresswire.com⁩/ -- VisCardia, Inc. is honored to announce that our team has won the judge’s vote during the Future Hub ACC.25 Innovation Pitch …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on November 5, 2024 - 11:00 GMT

  

  CMS Agrees With VisCardia on the Value of Synchronized Diaphragmatic Stimulation

  PORTLAND, OR, UNITED STATES, November 5, 2024 /⁨EINPresswire.com⁩/ -- VisCardia, Inc. announced today that they have received payment assignments for the designated CPT III codes for VisONE SDS® therapy by the Centers for Medicare and Medicaid Services ( …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on July 30, 2024 - 09:00 GMT

  

  VisCardia Receives US FDA IDE Approval to Start the RECOVER HF Clinical Study

  PORTLAND, OREGON, UNITED STATES, July 30, 2024 /⁨EINPresswire.com⁩/ -- VisCardia, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of an Investigational Device Exemption (IDE) to study the safety and effectiveness of the VisONE SDS …

  Distribution channels: Banking, Finance & Investment Industry, Companies ...